AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 11 min read$FLNA

Barry Richard purchased $278K of FLNA (indirect holdings)

Barry Richard (President & CEO) purchased 306,813 indirectly-held shares of FILANA THERAPEUTICS, INC. (FLNA) at an average of $0.91 ($0.90–$0.92, $0.28M total) across 2 trades over 2026-09-29 to 2026-09-30.

Original reporting
SEC EDGAR · Barry Richard
Published Oct 1, 2026, 11:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 12:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$FLNA
Bullish
medium confidence
Mentioned
$FLNA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FLNABullishLow
01

Why it matters

The transaction modestly raises the CEO's ownership, which could be interpreted as confidence in the company's prospects.

02

Market read

A small insider buy; likely limited immediate market effect but may be noted by analysts.

03

What to watch

Potential upcoming clinical milestones or financing needs not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: post‑filing today

Background

Form 4 filings disclose insider transactions; this filing reports a recent open‑market purchase by the CEO.

Company-level read

Ticker impact

$FLNABullishMedium confidence
Context

President & CEO Barry Richard bought 306,813 shares for $278K, increasing his stake to 1.34M shares.

Expected impact

modest upward pressure as market prices in insider confidence

Evidence & confidence

The purchase is relatively small for a public biotech, but it is a direct insider buy via open market, which traders often view as a positive signal.

Market effects

Sector

Minimal impact on biotech sector; typical insider buys have limited broader relevance.

Regional

None

Global

None

Counterpoint

What could challenge this read

The purchase size is modest and may be routine compensation, offering little real insight.

Key entities

  • person
    Barry Richard

    President & CEO of Filana Therapeutics, Inc.

  • company
    Filana Therapeutics, Inc.

    Biotech company developing therapies for rare diseases.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FLNA insider trading history →

Related articles

SEP 22
$FLNAMedAI 8/10

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organizatio

SEC EDGAR 8-K2 min
JUL 29
$FLNAMed

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing

SEC EDGAR 8-K4 min
OCT 23
$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).

SEC EDGAR1 min
OCT 22
$DOLELow

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $8.6M of DOLE (indirect holdings)

Pale Fire Capital SE purchased 648,356 indirectly-held shares of Dole plc (DOLE) at an average of $13.19 ($13.12–$13.39, $8.55M total) across 3 trades over 2026-10-20 to 2026-10-22. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).

SEC EDGAR1 min